The Emirates Drug Establishment (EDE) has approved Baxfendy to treat hypertension in patients who are unable to adequately control blood pressure levels through traditional medications.
Baxfendy contains the active substance baxdrostat, developed by AstraZeneca, which lowers blood pressure by inhibiting an enzyme responsible for aldosterone production. The drug is available in 1 mg and 2 mg doses.
“Approving this treatment is yet another significant step towards enabling advanced medical solutions that precisely target disease pathways, particularly in cases that do not respond to traditional options, while ensuring uninterrupted access for patients,” said Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment.
Hypertension is one of the most pressing health challenges in the UAE, with estimates indicating that approximately one in three adults is affected, making it among the most prevalent non-communicable diseases in the country.
Despite the availability of multiple treatment options, control rates remain below optimal levels, making the addition of the new medication a closer step to supporting the disease.
UAE postpones vehicle licensing limit for residents
UAE Government Annual Meetings key to reviewing national priorities
New pedestrian bridge links Dubai Mall Metro Station and Coca-Cola Arena
High-achieving Union teams honoured at UAE Government Annual Meetings
Al Gergawi: UAE accelerates development with over AED 4 trillion in projects
